On Jul. 15, 2020, BioAegis Therapeutics announced that it received regulatory clearance from The Spanish Agency for Medicines and Health Products for its Phase 2 Proof of Concept study of its lead product, recombinant human plasma gelsolin (rhu-pGSN) in hospitalized patients with severe COVID-19 pneumonia.

BioAegis expects to recruit its first patient and begin the study shortly at Hospital Universitari Sant Joan de Reus in Tarragona, Spain.